posted
When I pull this up on scottrade it has it at 60.00 a share, but my account says .035. Does anyone know why?
Posts: 14 | From: Texas | Registered: Sep 2005
| IP: Logged |
posted
Herborium Group, Inc. (PINKSHEETS: HBRM) (www.herborium.com), a botanical therapeutics(R) company that develops, licenses and markets all natural, herbal medicinal products, has focused its efforts on developing aggressive routes of taping into $33 billion over the counter alternative medicine market in the USA and over a trillion USD global market for alternative and complementary medicine. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage.
Herborium pipeline of botanical therapeutics in the sectors of dermatology (Acne -- global market is over 55 Billion USD and over 60 million Americans are diagnosed and affected yearly by different forms of acne -- www.acnease.com), women's and men's health, including BPH (benign prostate hyperplasia affects over half of male population at the age of 50+) and liver health, belong to the most growing category of CAM products (self care costs) that reached $22 Billion in the US last year with majority going to purchase of non-vitamin, and non-mineral products.
"With the conversion of such factors as health economics, directing consumers to spend money on prevention and on non ethical products (lower insurance coverage) and to pharmaceutical companies being forced to remove drugs from the market for safety reasons (La Roche and Accutane for acne or Vioxx for pain), Herborium is ideally positioned to take advantage of those emerging market opportunities," said Dr. Agnes P. Olszewski, President of Herborium Group. "During last four months we have focused our activities on preparing to penetrate new markets with our existing products including targeting of foreign markets. We have signed or are in final stage of negotiating new distribution agreements in the USA and abroad that will greatly increase our customer base. We expect that our bottom line will significantly benefit from those initiatives in 2010 and 2011," continues Dr. Olszewski.
"We are also planning to introduce new and complementary products. We are especially excited about expected product line extension in the field of dermatology with a product targeting acne," adds Dr. Olszewski
"While securing additional resources we plan to address needs of consumers and health providers that look for highly efficient, proven safe and effective all natural alternatives in treatment and prevention of number of health problems and concerns," concludes Dr. Olszewski
About Herborium Group, Inc. Herborium Group, Inc., a botanical therapeutics(R) company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the forms 10-Q.
-------------------- what i post is my opinion Posts: 304 | Registered: Sep 2009
| IP: Logged |
from microcap website they have 8 million shares to dump::::
http://www.microcapreports.com has not been compensated for this report however is an accredited investor and has purchased 10 million shares of AMSZ and 8 million shares of HBRM from a 3rd party debt holder from a non-controlling, non-affiliated 3rd party. We intend to sell our shares into market which could negatively affect the stock price. Investing in penny stocks is very risky and we invite anyone to please review the information provided by the SEC pertaining to penny stock rules http://www.sec.gov/
-------------------- Buy Low. Sell High. Posts: 10754 | From: The Land Of The Giants | Registered: Feb 2005
| IP: Logged |
posted
HBRM- Worldwide Demand For Natural Healthcare Alternatives Worldwide:$250 Billion (US/$60 Billion; EU/$50 Billion; UK /$25 Billion)*
It is expected that by 2010, 65% of doctors in the US will recommend herbal or alternative medicinal products and 67% of the US population will use natural medications or alternative therapies. Big Pharma currently lacks a pipeline in this sector.
Posts: 428 | From: Michigan | Registered: Oct 2009
| IP: Logged |
posted
from microcap website they have 8 million shares If they wanted to sell do they have to report a sale first
Posts: 195 | From: Florida | Registered: Feb 2010
| IP: Logged |
posted
HBRM Based on these public estimates the stock price of HBRM could soar up 790% in the near term and more than 2,327% this year.
With 68% margins and 200 million shares outstanding at 19X EPS…
Target Share Price = $.67 for 2010 and $1.34 for 2011
Herborium, Inc.’s (HBRM) business plan is to raise expansion capital for new healthcare market opportunities and reach $10 million in sales for 2010 with a gross profit margin of 68%. Then in 2011 the company’s projections are for $20 million in sales with a similar high gross profit margin.
-------------------- All material posted by this poster is for informational purposes only Posts: 213 | Registered: Dec 2008
| IP: Logged |
Marketwire "Press Releases " NEW YORK, NY -- (MARKET WIRE) -- 06/01/10 -- Herborium Group, Inc. (PINKSHEETS: HBRM) announced that they are focusing their efforts on developing aggressive routes to tapping into the over the counter alternative medicine and complementary medicine market.
Plants have been used as a source of medicine throughout history and continue to serve as the basis for many pharmaceuticals used today. Although the modern pharmaceutical industry was born from botanical medicine, synthetic approaches to drug discovery have become standard. However, this modern approach has led to a decline in new drug development in recent years and a growing market for botanical therapeutics that are currently available as dietary supplements, drugs, or botanical drugs. Herborium initially aims to take on some of the most wide reaching afflictions that affect Americans, acne and benign prostate hyperplasia (BPH). These two focuses open up a 77 billion dollar market.
Posts: 143 | Registered: Apr 2010
| IP: Logged |
posted
Herborium Group, Inc. (PINKSHEETS: HBRM) (www.herborium.com), a botanical therapeutics company that develops, licenses and markets all natural, herbal medicinal products, has focused its efforts on developing aggressive routes of taping into $33 billion over the counter alternative medicine market in the USA and over a trillion USD global market for alternative and complementary medicine.
The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage.
Herborium pipeline of botanical therapeutics in the sectors of dermatology (Acne -- global market is over 55 Billion USD and over 60 million Americans are diagnosed and affected yearly by different forms of acne -- www.acnease.com), women's and men's health, including BPH (benign prostate hyperplasia affects over half of male population at the age of 50+) and liver health, belong to the most growing category of CAM products (self care costs) that reached $22 Billion in the US last year with majority going to purchase of non-vitamin, and non-mineral products.
"With the conversion of such factors as health economics, directing consumers to spend money on prevention and on non ethical products (lower insurance coverage) and to pharmaceutical companies being forced to remove drugs from the market for safety reasons (La Roche and Accutane for acne or Vioxx for pain), Herborium is ideally positioned to take advantage of those emerging market opportunities," said Dr. Agnes P. Olszewski, President of Herborium Group. "During last four months we have focused our activities on preparing to penetrate new markets with our existing products including targeting of foreign markets. We have signed or are in final stage of negotiating new distribution agreements in the USA and abroad that will greatly increase our customer base. We expect that our bottom line will significantly benefit from those initiatives in 2010 and 2011," continues Dr. Olszewski.
"We are also planning to introduce new and complementary products. We are especially excited about expected product line extension in the field of dermatology with a product targeting acne," adds Dr. Olszewski
"While securing additional resources we plan to address needs of consumers and health providers that look for highly efficient, proven safe and effective all natural alternatives in treatment and prevention of number of health problems and concerns," concludes Dr. Olszewski
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the forms 10-Q.
-------------------- what i post is my opinion Posts: 304 | Registered: Sep 2009
| IP: Logged |
posted
Herborium Group Commences AcnEase(R) Retail Sales
Posted by: kairos Date: Wednesday, June 02, 2010 4:02:53 PM In reply to: None Post # of 1619
Herborium Group Commences AcnEase(R) Retail Sales AcnEase(R) Now Available in New York Dermatology Clinics Jun 2, 2010 3:00:00 PM
Close Ad Email story | Discuss on ZenoBank | View more ads SADDLE BROOK, NJ -- (MARKET WIRE) -- 06/02/10 -- Herborium Group, Inc., (PINKSHEETS: HBRM), a Botanical Therapeutics? company, today announced it has now successfully secured direct consumer points-of-sale for its flagship product, AcnEase®, with a recognized group of New York dermatological clinics.
"Acceptance of AcnEase by board certified dermatologist to be sold in the clinics is a major third-party validation of the therapeutic value of our product, and is an important cornerstone in building the AcnEase® brand," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer.
AcnEase® is a proprietary, all herbal, systemically acting botanical therapeutic targeting acne symptom in both females and males of all ages, and has been proven safe and effective through clinical testing. Test results have demonstrated that in adolescent acne, approximately 95% of patients responded positively to AcnEase. In individuals above age 31, the level of effectiveness was 80%. The overall positive response rate to AcnEase was 91%. After more than five years of online sales, Herborium has consistently registered over 95% consumer satisfaction rating (www.acnease.com).
Dr. Olszewski continued, "Expanding beyond e-commerce (internet sales) to direct consumer points-of-sale is an important milestone in our overall plan to increase AcnEase sales and brand recognition and grow market share within the US 3.5 billion over the counter medicated skin care market
"With the current surge in sales of over-the-counter nutritional and health supplements, combined with Hoffmann-La Roche Inc.'s announcement to discontinue marketing of its leading treatment for severe acne, Accutane® (isotretinoin), and Herborium's AcnEase product's demonstrated and documented over five year history of safe and effective acne treatment, I firmly believe we have the right product, at the right time, for over 50 million acne sufferers in the USA.
"Having successfully launched our direct-to-consumer sales strategy with AcnEase in the US market , we intend to replicate this strategy to the extent justified "by market conditions" in International markets, while we prepare our next product sales initiative to access the US cosmeceutical market expected to potentially reach over $16 billion by 2010.
"Herborium is committed to continue developing a global brand with a strong international distribution network, and the acceptance of AcnEase by the dermatological community is a key development in both product branding and sales growth strategies," Dr. Olszewski concluded.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.
One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. Company Contact: Dr. Agnes P. Olszewski President & CEO (201) 647-3757 (201) 647-3757
Posts: 364 | Registered: Mar 2010
| IP: Logged |
posted
Herborium Group, Inc., is a novel botanical therapeutics® company focused on developing, licensing, and marketing of proprietary, botanical based medicinal products, targeting unmet medical needs. The Company responds to both consumers and healthcare professionals demand for safe, efficacious, all natural medicinal options for treatment and prevention of selected diseases and health concerns
Posts: 364 | Registered: Mar 2010
| IP: Logged |
posted
The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The potential for this market assesses for over $125 Billon in the USA and UK alone
Posts: 364 | Registered: Mar 2010
| IP: Logged |
posted
Capitalizing on the increased trend for natural and organic products in Healthcare, Food and Personal Care, Herborium Group Inc. offers what constitutes the complete natural medicinal solution. We are an industry innovator and our goal is to attract, educate and maintain high involvement clients in both commercial and consumer markets. Our mantra is the intense use of proprietary and superior natural medicinal products supported by the application of interactive and customized marketing strategies.
Posts: 364 | Registered: Mar 2010
| IP: Logged |
posted
The Market potential for this sector worldwide is $250 billion and growing, with over $60 billion a year already spent in the USA in the natural and alternative healthcare sector.
Posts: 364 | Registered: Mar 2010
| IP: Logged |
E-Commerce & Affiliates Natural Health Products and Natural Food stores& Chains Specialty High-end Apothecaries, National Upscale Pharmacy chains Healthcare Professional Market SPAs / Health & Beauty Ethnic Markets Wholesale Market
Global Distribution
E-Commerce & Affiliates Presence in UK & Germany Initial Presence in Japan Market Entry into India & Brazil Healthcare Professional Markets SPAs / Health & Beauty Wholesale Market Targeted Markets ( e.g. male market)
Posts: 364 | Registered: Mar 2010
| IP: Logged |
posted
HBRM - AcnEase is the only clinically tested herbal treatment for acne. See Improvement in 7 to 10 Days http://www.herborium.comPosts: 428 | From: Michigan | Registered: Oct 2009
| IP: Logged |
posted
AcnEase means fast and safe results AcnEase is different because it treats the causes of acne, not just the symptoms. It improved acne conditions in more than 95% of patients in clinical studies, and noticeable results often take only 7 to 10 days. It also works on all acne types and skin types, including darker skin tones.
Unlike other products that contain antibiotics, benzoyl peroxide, or salicylic acid, AcnEase is proven safe and has no side effects like dry and irritated skin.
Posts: 428 | From: Michigan | Registered: Oct 2009
| IP: Logged |
posted
HBRM.PK traded up yesteray closing the day at $.0275, a gain of nearly 6% on heavy volume of 2.7 million shares. That sent the company to it's fourth day of higher closes day over day. This trend looks to continue with the news released at the bell yesterday.
Posts: 428 | From: Michigan | Registered: Oct 2009
| IP: Logged |
posted
HBRM has tremendous potential. Volume is always key in trading any stock and HBRM is definately attracting significant volume these days.
Posts: 428 | From: Michigan | Registered: Oct 2009
| IP: Logged |
posted
Herborium Group, Inc., (PINKSHEETS: HBRM), a Botanical Therapeutics(TM) company, today announced it has now successfully secured direct consumer points-of-sale for its flagship product, AcnEase(R), with a recognized group of New York dermatological clinics. "Acceptance of AcnEase by board certified dermatologist to be sold in the clinics is a major third-party validation of the therapeutic value of our product, and is an important cornerstone in building the AcnEase(R) brand," commented Dr. Agnes P. Olszewski, Herborium Group's president and chief executive officer.
AcnEase(R) is a proprietary, all herbal, systemically acting botanical therapeutic targeting acne symptom in both females and males of all ages, and has been proven safe and effective through clinical testing. Test results have demonstrated that in adolescent acne, approximately 95% of patients responded positively to AcnEase. In individuals above age 31, the level of effectiveness was 80%. The overall positive response rate to AcnEase was 91%. After more than five years of online sales, Herborium has consistently registered over 95% consumer satisfaction rating (www.acnease.com).
Dr. Olszewski continued, "Expanding beyond e-commerce (internet sales) to direct consumer points-of-sale is an important milestone in our overall plan to increase AcnEase sales and brand recognition and grow market share within the US 3.5 billion over the counter medicated skin care market
"With the current surge in sales of over-the-counter nutritional and health supplements, combined with Hoffmann-La Roche Inc.'s announcement to discontinue marketing of its leading treatment for severe acne, Accutane(R) (isotretinoin), and Herborium's AcnEase product's demonstrated and documented over five year history of safe and effective acne treatment, I firmly believe we have the right product, at the right time, for over 50 million acne sufferers in the USA.
"Having successfully launched our direct-to-consumer sales strategy with AcnEase in the US market , we intend to replicate this strategy to the extent justified "by market conditions" in International markets, while we prepare our next product sales initiative to access the US cosmeceutical market expected to potentially reach over $16 billion by 2010.
"Herborium is committed to continue developing a global brand with a strong international distribution network, and the acceptance of AcnEase by the dermatological community is a key development in both product branding and sales growth strategies," Dr. Olszewski concluded.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics(R) company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.
One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time they are issued, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. Adino Energy Corporation urges investors to review the risks and uncertainties contained within its filings with the Securities and Exchange Commission.
-------------------- what i post is my opinion Posts: 304 | Registered: Sep 2009
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
